Journalartikel
Autorenliste: Howard, Luke S. G. E.; He, Jianguo; Watson, Geoffrey M. J.; Huang, Li; Wharton, John; Luo, Qin; Kiely, David G.; Condliffe, Robin; Pepke-Zaba, Joanna; Morrell, Nicholas W.; Sheares, Karen K.; Ulrich, Anna; Quan, Ruilin; Zhao, Zhihui; Jing, Xiaoli; An, Chenhong; Liu, Zhihong; Xiong, Changming; Robbins, Peter A.; Dawes, Timothy; de Marvao, Antonio; Rhodes, Christopher J.; Richter, Manuel J.; Gall, Henning; Ghofrani, Hossein A.; Zhao, Lan; Huson, Les; Wilkins, Martin R.
Jahr der Veröffentlichung: 2021
Seiten: 981-988
Zeitschrift: Proceedings of the American Thoracic Society
Bandnummer: 18
Heftnummer: 6
ISSN: 1546-3222
eISSN: 2325-6621
Open Access Status: Hybrid
DOI Link: https://doi.org/10.1513/AnnalsATS.202009-1131OC
Verlag: American Thoracic Society
Rationale: Iron deficiency, in the absence of anemia, is common in patients with idiopathic and heritable pulmonary arterial hypertension (PAH) and is associated with a worse clinical outcome. Oral iron absorption may be impeded by elevated circulating hepcidin concentrations. The safety and benefit of parenteral iron replacement in this patient population is unclear. Objectives: To evaluate the safety and efficacy of parenteral iron replacement in PAH. Methods: In two randomized, double-blind, placebo-controlled 12-week crossover studies, 39 patients in Europe received a single infusion of ferric carboxymaltose (Ferinject) (1,000 mg or 15 mg/kg if weight <66.7 kg) or saline as placebo, and 17 patients in China received iron dextran (Cosmofer) (20 mg iron/kg body weight) or saline placebo. All patients had idiopathic or heritable PAH and iron deficiency at entry as defined by a serum ferritin <37 mu g/L or iron <10.3 mu mol/L or transferrin saturations <16.4%. Results: Both iron treatments were well tolerated and improved iron status. Analyzed separately and combined, there was no effect on any measure of exercise capacity (using cardiopulmonary exercise testing or 6-minute walk test) or cardiopulmonary hemodynamics, as assessed by right heart catheterization, cardiac magnetic resonance, or plasma NT-proBNP (N-terminal-pro hormone brain natriuretic peptide) at 12 weeks. Conclusions: Iron repletion by administration of a slow-release iron preparation as a single infusion to patients with PAH with iron deficiency without overt anemia was well tolerated but provided no significant clinical benefit at 12 weeks.
Abstract:
Zitierstile
Harvard-Zitierstil: Howard, L., He, J., Watson, G., Huang, L., Wharton, J., Luo, Q., et al. (2021) Supplementation with Iron in Pulmonary Arterial Hypertension Two Randomized Crossover Trials, Proceedings of the American Thoracic Society, 18(6), pp. 981-988. https://doi.org/10.1513/AnnalsATS.202009-1131OC
APA-Zitierstil: Howard, L., He, J., Watson, G., Huang, L., Wharton, J., Luo, Q., Kiely, D., Condliffe, R., Pepke-Zaba, J., Morrell, N., Sheares, K., Ulrich, A., Quan, R., Zhao, Z., Jing, X., An, C., Liu, Z., Xiong, C., Robbins, P., ...Wilkins, M. (2021). Supplementation with Iron in Pulmonary Arterial Hypertension Two Randomized Crossover Trials. Proceedings of the American Thoracic Society. 18(6), 981-988. https://doi.org/10.1513/AnnalsATS.202009-1131OC
Schlagwörter
FERRIC CARBOXYMALTOSE; iron dextran; pulmonary arterial hypertension; QUALITY-OF-LIFE
